期刊文献+
共找到638篇文章
< 1 2 32 >
每页显示 20 50 100
Clinical study of chemotherapy-related cognitive impairment in patients with non-Hodgkin lymphoma
1
作者 Qiang-Li Wang Hai-Yan Xu +3 位作者 Yi Wang Yin-Ling Wang Pei-Nan Lin Zhong-Lei Chen 《World Journal of Psychiatry》 SCIE 2024年第7期1062-1067,共6页
BACKGROUND Chemotherapy for malignant tumors can cause brain changes and cognitive impairment,leading to chemotherapy-induced cognitive impairment(CICI).Current research on CICI has focused on breast cancer and Hodgki... BACKGROUND Chemotherapy for malignant tumors can cause brain changes and cognitive impairment,leading to chemotherapy-induced cognitive impairment(CICI).Current research on CICI has focused on breast cancer and Hodgkin’s lymphoma.Whether patients with non-Hodgkin’s lymphoma(NHL)undergoing chemo-therapy have cognitive impairment has not been fully investigated.therapy have cognitive impairment has not been fully investigated.AIM To investigate whether NHL patients undergoing chemotherapy had cognitive impairments.METHODS The study included 100 NHL patients who were required to complete a compre-hensive psychological scale including the Brief Psychiatric Examination Scale(MMSE)at two time points:before chemotherapy and within 2 wk of two chemo-therapy courses.A language proficiency test(VFT),Symbol Number Pattern Test(SDMT),Clock Drawing Test(CDT),Abbreviated Daily Cognition Scale(ECog-12),Prospective and Retrospective Memory Questionnaire,and Karnofsky Perfor-mance Status were used to assess cognitive changes before and after chemo-therapy.RESULTS The VFT scores for before treatment(BT)and after treatment(AT)groups were 45.20±15.62,and 42.30±17.53,respectively(t-2.16,P<0.05).The CDT scores were 8(3.5-9.25)for BT and 7(2.5-9)for AT groups(Z-2.1,P<0.05).Retrospective memory scores were 13.5(9-17)for BT and 15(13-18)for AT(Z-3.7,P<0.01).The prospective memory scores were 12.63±3.61 for BT and 14.43±4.32 for AT groups(t-4.97,P<0.01).The ECog-12 scores were 1.71(1.25-2.08)for BT and 1.79(1.42-2.08)for AT groups(Z-2.84,P<0.01).The SDMT and MMSE values did not show a significant difference between BT and AT groups.CONCLUSION Compared to the AT group,the BT group showed impaired language,memory,and subjective cognition,but objec-tive cognition and execution were not significantly affected. 展开更多
关键词 non-hodgkins lymphoma Hodgkin lymphoma lymphoma cognitive impairment Chemotherapy-related cogni-tive impairment Clinical study
下载PDF
Absence of enhancement in a lesion does not preclude primary central nervous system T-cell lymphoma:A case report
2
作者 Chan-Seop Kim Chi-Hoon Choi +4 位作者 Kyung Sik Yi Yook Kim Jisun Lee Chang Gok Woo Young Hun Jeon 《World Journal of Clinical Cases》 SCIE 2024年第2期374-382,共9页
BACKGROUND Primary central nervous system lymphoma(PCNSL)is a non-Hodgkin lymphoma that originates in the central nervous system(CNS)and is exclusively limited to the CNS.Although most PCNSLs are diffuse large B-cell ... BACKGROUND Primary central nervous system lymphoma(PCNSL)is a non-Hodgkin lymphoma that originates in the central nervous system(CNS)and is exclusively limited to the CNS.Although most PCNSLs are diffuse large B-cell lymphomas,primary CNS T-cell lymphomas(PCNSTLs)are rare.PCNSTLs typically demonstrate some degree of enhancement on contrast-enhanced magnetic resonance imaging(MRI).To the best of our knowledge,non-enhancing PCNSTL has not been reported previously.CASE SUMMARY A 69-year-old male presented to the neurology department with complaints of mild cognitive impairment and gradual onset of left lower leg weakness over a span of two weeks.Initial MRI showed asymmetric T2-hyperintense lesions within the brain.No enhancement was observed on the contrast-enhanced T1 image.The initial diagnosis was neuro-Behçet’s disease.Despite high-dose steroid therapy,no alterations in the lesions were identified on initial MRI.The patient’s symptoms deteriorated further.An MRI performed one month after the initial scan revealed an increased lesion extent.Subsequently,brain biopsy confirmed the diagnosis of PCNSTL.The patient underwent definitive combined chemoradiotherapy.However,the patient developed bacteremia and died of septic shock approximately three months after diagnosis.CONCLUSION The absence of enhancement in the lesion did not rule out PCNSTL.A biopsy approach is advisable for pathological confirmation. 展开更多
关键词 Central nervous system neoplasms non-hodgkin lymphoma T-cell lymphoma Primary central nervous system lymphoma Primary central nervous system T-cell lymphoma Case report
下载PDF
SENEX-mediated CDK4/6 inhibition promotes senescence and confers apoptosis resistance in B-cell non-Hodgkin lymphoma
3
作者 JIYU WANG LIUYING YI +3 位作者 KEKE HUANG YANGYANG WANG HUIPING WANG ZHIMIN ZHAI 《BIOCELL》 SCIE 2024年第3期453-462,共10页
Background:The primary cause of treatment failure in patients with refractory or relapsed B-cell non-Hodgkin lymphoma(r/r B-NHL)is resistance to current therapies,and therapy-induced senescence(TIS)stands out as a cru... Background:The primary cause of treatment failure in patients with refractory or relapsed B-cell non-Hodgkin lymphoma(r/r B-NHL)is resistance to current therapies,and therapy-induced senescence(TIS)stands out as a crucial mechanism contributing to tumor drug resistance.Here,we analyzed SENEX/Rho GTPase Activating Protein 18(ARHGAP18)expression and prognostic significance in doxorubicin-induced B-NHL-TIS model and r/r B-NHL patients,investigating its target in B-NHL cell senescence and the effect of combining specific inhibitors on apoptosis resistance in B-NHL-TIS cells.Methods:Raji cells were transfected with the human SENEX shRNA recombinant lentiviral vector(Sh-SENEX)and the empty vector negative(NC)to construct a stable transfection cell line with knockdown of SENEX.Effect of SENEX-silencing on B-NHL-TIS formation,cell function and cell cycle-related pathways was analyzed.Using doxorubicin(DOX)-inducible senescent B-NHL cells combined with the specific cyclin dependent kinase 4/6(CDK4/6)inhibitor Palbociclib to observe that blocking CDK4/6 effects on TIS formation.SENEX expression of 21 B-NHL patients and 8 healthy controls were analyzed by qRT-PCR,and the correlation between its expression and clinical indicators were evaluated.Results:The downregulation of SENEX expression promotes G1-S phase transition and apoptosis while inhibiting cell proliferation,collectively suppressing the formation of TIS in B-NHL.Blockade of CDK4/6 promotes the DOX-induced G1 phase arrest to enhance TIS formation in B-NHL cells which can reverse the regulatory effect of silencing SENEX on B-NHL cell cycle regulation and senescence.The expression levels of SENEX were notably elevated in B-NHL patients compared to healthy controls,and Elevated expression levels of SENEX were associated with poor prognosis of B-NHL patients.Conclusions:SENEX enhances apoptosis resistance in B-NHL by inhibiting CDK4/6,thereby preventing G1-S phase transition and promoting TIS formation. 展开更多
关键词 sENEX B-cell non-hodgkin lymphoma CDK4/6 G1-s phase transition Therapy-induced senescence Apoptosis resistance
下载PDF
Primary Non-Hodgkin’s Malignant Lymphoma of the Uterus at the Reference Hospital of Maradi/Niger: A Case Report
4
作者 Moustapha Elhadji-Chefou Badé Malam-Abdou +5 位作者 Amadou Djibrilla-Almoustapha Maman Brah Moustapha Oumou Kimso Ibrahim Timi Liman Elhadji Ali Issa Abdou Amadou Borges Moreno Yuribet 《Open Journal of Blood Diseases》 2024年第2期43-46,共4页
Malignant non-Hodgkins lymphoma (MHNL) of the uterus is uncommon. We report a case diagnosed on the basis of histologic and immunohistochemical studies of a hysterectomy specimen induced by a very painful pelvic mass ... Malignant non-Hodgkins lymphoma (MHNL) of the uterus is uncommon. We report a case diagnosed on the basis of histologic and immunohistochemical studies of a hysterectomy specimen induced by a very painful pelvic mass in a 50-year-old patient with no previous history of the disease. It was classified as Ann Arbor IV Bb after imaging, given the medullary infiltration and signs of clinical and biological evolutivity: the patient had received two courses of chemotherapy, CHOP protocol. She died 23 days after the second treatment due to a hypertensive crisis. 展开更多
关键词 Malignant non-hodgkins lymphoma UTERUs Referral Hospital Maradi/Niger
下载PDF
Primary Pleural Extranodal Non-Hodgkin's Lymphoma Presenting As Pleural Thickening-A Case Report
5
作者 Pradipta Guha Debasis Sarkar +3 位作者 Arindam Ray Indranil Thakur Sekhar Mukherjee Sanjoy Kumar Chatterjee 《Clinical oncology and cancer researeh》 CAS CSCD 2011年第1期47-50,共4页
Primary pleural lymphoma is a rare entity that has been described in association with human immunodeficiency virus (HIV) infection or pyothorax. This paper reports on a 27 year old man with no history of HIV infecti... Primary pleural lymphoma is a rare entity that has been described in association with human immunodeficiency virus (HIV) infection or pyothorax. This paper reports on a 27 year old man with no history of HIV infection or pyothorax who presented with progressive dyspnea and heaviness of chest.Chest radiography revealed complete opacification of the left hemithorax, and contrast enhanced computed tomography showed large left pleural effusion and homogeneous, extensive thickening of the parietal pleura. CT guided biopsy of thickened pleura is suggestive of non-Hodgkin's lymphoma-T cell lymphoblastic variety. Physicians should be aware of this rare location of primary pleural lymphoma manifested by thickening of the pleura. 展开更多
关键词 non-hodgkin's lymphoma T cell lymphoblastic type lymphoma extranodal NK-T-cell
下载PDF
The expression of cyclooxygenase-2 (COX-2) and p16 in non-Hodgkin's lymphomas and its clinical significance 被引量:4
6
作者 Xigui Yang Huazhi Zhang +1 位作者 Ling Wei Liya Jia 《The Chinese-German Journal of Clinical Oncology》 CAS 2009年第2期104-109,共6页
Objective: To investigate the expression of cyclooxygenase-2 (COX-2) and p16 proteins in non-Hodgkin's lymphomas (NHL) and their relationship with the genesis and progress of it. Methods: The expression of COX-... Objective: To investigate the expression of cyclooxygenase-2 (COX-2) and p16 proteins in non-Hodgkin's lymphomas (NHL) and their relationship with the genesis and progress of it. Methods: The expression of COX-2 and p16 protein were studied in the lymph nodes tissue from 60 NHL patients and 10 control patients with non-malignant diseases by flow cytometry. Results: Positive rate of COX-2 protein expression in NHL tissues (63.3%, 38/60) was higher than that in normal lymphaden tissues (0, 0/10). The difference was significant between the two groups (P 〈 0.01). Expression of COX-2 protein was related with the clinical stage of NHL. In stage Ⅰ + Ⅱ patients, it was significantly lower (35.0% ± 54.6%) than that in stage Ⅲ + Ⅳ patients (84.6% ±87.5%) (P 〈 0.01). In different sex, age, tumor malignant degree, IPI grade, extranodal involvement and B symptoms groups, the differences of COX-2 expression were not statistically significant (P 〉 0.05). Positive rate of p16 protein expression (41.7%, 25/60) in NHL' was statistically lower than that in normal lymphomas (100%, 10/10) (P 〈 0.01). Expression of p16 protein was related to malignant degree of NHL. The positive rates of p16 protein in low malignant degree tissues (64.7%, 11/17) was higher than that in high malignant degree tissues (14.3%, 2/14) (P 〈 0.05). Positive rates of p16 protein of NHL tissues in different sex, age, IPI grade, extranodal involvement, clinical stages and B symptoms were not statistically significant (P 〉 0.05). The p16 protein expression in COX-2 positive patients was 47.4% (18/38), and in negative patients it was 31.8% (7/22). There was no statistically difference between them (P 〉 0.05). Correlation analysis revealed there was no correlation between expression of COX-2 and p16 protein. Conclusion: Both COX-2 and p16 protein may all have relationship with the genesis and progress of NHL. The expression of COX-2 protein in NHL may be a poor prognostic indicator. COX-2 and p16 protein probably have different mechanisms in the genesis and progress of NHL. Their relationship is firstly put forward in this article and needed further studying. 展开更多
关键词 non-hodgkin's lymphomas p16 protein CYCLOOXYGENAsE-2 flow cytometry
下载PDF
Phase I study of chimeric anti-CD20 monoclonal antibody in Chinese patients with CD20-positive non-Hodgkin's lymphoma 被引量:6
7
作者 Lin Gui Xiaohong Han +10 位作者 Xiaohui He Yuanyuan Song Jiarui Yao Jianliang Yang Peng Liu Yan Qin Shuxiang Zhang Weijing Zhang Wenlin Gai Liangzhi Xie Yuankai Shi 《Chinese Journal of Cancer Research》 SCIE CAS CSCD 2016年第2期197-208,共12页
Objective: This study was designed to determine the safety, pharmacokinetics and biologic effects of a humanmouse chimeric anti-CD20 monoclonal antibody (SCT400) in Chinese padents with CD20-positive B-cell non- Ho... Objective: This study was designed to determine the safety, pharmacokinetics and biologic effects of a humanmouse chimeric anti-CD20 monoclonal antibody (SCT400) in Chinese padents with CD20-positive B-cell non- Hodgkin's lymphoma (CD20 B-cell NHL). SCT400 has an identical amino acid sequence as rituximab, with the exception of one amino acid in the CH1 domain of the heavy chain, which is common in Asians. Methods: Fifteen patients with CD20+ B-cell NHL received dose-escalating SCT400 infusions (250 mg/m2: n=3; 375 mg/m2: n=9; 500 mg/m2: n=3) once weekly for 4 consecutive weeks with a 24-week follow-up period. The data of all patients were collected for pharmacoklnetics and pharmacodynamics analyses. Results: No dose-limiting toxicities were observed. Most drug-related adverse events were grade 1 or 2. Two patients had grade 3 or 4 ncutropenia. Under premedication, the drug-related infusion reaction was mild. A rapid, profound and durable depletion of circulating B cells was observed in all dose groups without significant effects on T cell count, natural killer (NK) cell count or immunoglobulin levels. No patient developed anti- SCT400 antibodies during the course of the study. SCT400 serum half-life (Tin), maximum concentration (Cmax and area under the curve (AUC) generally increased between the first and fourth infusions (P〈0.05). At the 375 mg/m2 dose, the T1/2 was 122.5±46.7 h vs. 197.0,75.0 11, respectively, and the Cmax was 200.6±20.2 pg/mL vs. 339.1±71.0 ng/mL, respectively. From 250 mg/m2 to 500 mg/m2, the Cmax and AUC increased significantly in a dose-dependent manner (P〈0.05). Patients with a high tumor burden had markedly lower serum SCT400 concenmations compared with those without or with a low tumor burden. Of the 9 assessable patients, 1 achieved complete response and 2 achieved partial responses. Conclusions; SCT400 is well-tolerated and has encouraging preliminary efficacy in Chinese patients with CD20+ B-cell NHL. 展开更多
关键词 Chimeric anti-CD20 monodonal antibody non-Hodgldn's lymphoma phase I study
下载PDF
Analysis of Prognostic Factors in 108 Patients with Non-Hodgkin's Lymphoma
8
作者 Jia-ming TANG An-wei CHEN +3 位作者 Wen-ming PENG Zi-ke QIN Guo-hua LIANG Qian QU 《Clinical oncology and cancer researeh》 CAS CSCD 2010年第1期44-47,共4页
OBJECTIVE To analyze the prognostic factors in patients with non-Hodgkin's lymphoma (NHL) and to investigate the prognostic value of the absolute lymphocyte count (ALC) in peripheral blood in NHL patients at admi... OBJECTIVE To analyze the prognostic factors in patients with non-Hodgkin's lymphoma (NHL) and to investigate the prognostic value of the absolute lymphocyte count (ALC) in peripheral blood in NHL patients at admission. METHODS The clinical features and follow-up data from 108 NHL patients whose diagnosis was confirmed through pathologic examination during a period from January 2000 to January 2008 were reviewed. SPSS 14.0 package was used for statistical analysis, and the Kaplan-Meier curve method for assessment of survival probability. Furthermore, the Cox regression model was utilized for multivariate analysis for all parameters which were statistically significant and confirmed by univariate analysis. RESULTS In the 108 NHL patients, the male-female ratio was approximately 1.5 : 1 and the median age was 48 years. Before treatment, 61.1% of the patients had stage I and II disease, based on the Ann Arbor Clinical Classification. The ECOG performance status (PS) score reached a range from 0 to 1 in about 93% of total patients, and an elevated serum lactate dehydrogenase (LDH) was seen in 19.2%. Based on the international prognostic index (IPI) score, 80.6% of patients were in the low risk group. On admission, 35.2% of patients had an ALC 〈 1 × 10^9/L. Anemia, i.e. hemoglobin (Hb) 〈 110 g/L was seen in 29.6% and B-symptoms in 26.9% of patients. The mean value of Hb was 129.2 + 17.5 g/L in patients with ALC 〉 1 x 109/L (n = 70) and 98.1 + 20.6 g/L in those with ALC 〈 1 × 10^9/L (n = 38), and the difference between the 2 groups was statistically significant (P 〈 0.05). With a median follow-up period of 2 years, the median survival time was 2.3 years among all patients. The 2-year and 5-year overall survival (OS) rates were 73.2% and 39.6%, respectively. It was shown by univariate analysis that ALC 〈 1 × 10^9/L, Hb ≤ 110 g/L, B-symptoms, and the IPI 〉 2 were statistically significant unfavorable prognostic factors in NHL patients. Multivariate analysis revealed that ALC 〈 1 × 10^9/L, B-symptoms, and the IPI 〉 2 were independent unfavorable prognostic factors in NHL patients. CONCLUSION The numerical value of ALC and the presence" of B-symptoms are prognostic factors independent of IPI in NHL patients. Clinically, determining prognosis based on the IPI combined with simple clinical parameters, such as the numerical value of ALC and B-symptom status, might be of more practical value in determining individualized treatment regimens for NHL patients. 展开更多
关键词 lymphocyte count non-hodgkin's lymphoma prognosis.
下载PDF
CHOP-like Regimen in Combination with Rituximab and Peginterferon Alpha-2b in Newly-diagnosed Diffuse Large B-cell Non-Hodgkin's Lymphoma: Experience in a Chinese Center
9
作者 Shu-qing LU Jian-min YANG Xian-min SONG Li CHEN Wei-ping ZHANG Xiao-qian XU Xiong NI Chong-mei HUANG Yi HE Jian-min WANG 《Clinical oncology and cancer researeh》 CAS CSCD 2010年第2期103-109,共7页
OBJECTIVE To evaluate the efficacy of rituximab combined with CHOP-like regimen with or without IFN in patients newly diagnosed diffuse large B-cell Non-Hodgkin's lymphoma (DLBCL).METHODS From January 2003 to July ... OBJECTIVE To evaluate the efficacy of rituximab combined with CHOP-like regimen with or without IFN in patients newly diagnosed diffuse large B-cell Non-Hodgkin's lymphoma (DLBCL).METHODS From January 2003 to July 2008, 51 patients received CHOP-like chemotherapy (cyclophosphamide 750 mg/m2, epirubicin 80 mg/m2, vindesine 2.8 mg/m2 on day 1, and prednisolone 100 mg/day on day 1 to day 5). Thirty-one patients received CHOPR-like treatment (rituximab 375 mg/m2 1 day before CHOP-like chemotherapy). Twenty patients received CHOP-like regimen in combination with peginterferon (pegIFN) (1μg/kg on day 5) and rituximab (on day 6).RESULTS -The CR (complete remission) rate in the CHOPR-like (with or without pegIFN) group and in the CHOP-like group was 78.4% and 45.1% (P = 0.005), respectively. The estimated mean time of overall survival (OS) in the CHOPR-like group and CHOP- like group was 58.7 ± 2.8 and 36.4 ±3.4 months, respectively (P = 0.002). The rates of CR and OR (overall remission) in CHOPR- like with IFN arm were 85.0% and 95.0%, and the rates of those in CHOPR-like without IFN arm were 74.2% and 87.0% (P 〉 0.05). The estimated mean time of 4-year-PFS (progression- free survival) in CHOPR-like with IFN arm and in CHOPR-like without IFN arm was 62.9 ±3.0 months and 51.0 ± 4.6 months (P = 0.092), respectively. In the CHOPR-like with IFN arm, no patient relapsed after achieving CR, while the estimated rate of 4-year- DFS (disease-free survival) in the patients who reached CR in the CHOPR-like without IFN arm was (63.4 ± 19.3)% (P = 0.061). CONCLUSION Rituximab combined with CHOP-like chemotherapy improved the prognosis of DLBCL patients. The IFN may help to improve the quality and duration of response of DLBCL patients treated with rituximab and CHOP-like regimen. 展开更多
关键词 CHOP-like RITUXIMAB peginte feron alpha-2b non-hodgkin's lymphoma diffuse large B-cell.
下载PDF
Superior Antitumor Activity of Rituximab-Conjugated and Maytansine-Loaded PLA-TPGS Nanoparticles in Xenograft Models for Non-Hodgkin's Lymphoma
10
作者 Xiaolong Tang Yuan Fang +9 位作者 Yongqiang Zhu Jingjing Dai Ganxun Wang Yajuan Liu Rongbo Zhang Shuyu Cai Jinfeng Zhang Keliang Song Lifa Xu Yong Liang 《Journal of Pharmacy and Pharmacology》 2014年第6期336-348,共13页
The increased incidence ofNHL (non-Hodgkin's lymphoma), along with its high mortality rate and pronounced resistance to therapy pose an enormous challenge. Both traditional therapeutic strategies and recently devel... The increased incidence ofNHL (non-Hodgkin's lymphoma), along with its high mortality rate and pronounced resistance to therapy pose an enormous challenge. Both traditional therapeutic strategies and recently developed therapeutic strategies against NHL such as chemoimmunotherapy and targeted therapy have drawbacks. Therefore, novel therapeutic approaches for NHL are urgently needed. Maytansine-loaded PLA-TPGS (polyethylene glycol 1000 succinate-polylactide) nanoparticles were synthesized. And then, rituximab targeting NHL was conjugated together by using EDC (1-ethyl-3-(3-dimethylaminopropyl) carbodiimide) as a coupling agent. The in vitro/vivo antitumor activity was evaluated by Raji cell proliferation inhibition and nude mice xenograft tumor models for NHL. Both the rituximab-conjugated and maytansine-loaded PLA-TPGS nanoparticles (maytansine-NPs (Nanoparticles)-rituximab) and maytansine-loaded PLA-TPGS nanoparticles (maytansine-NPs) presented significant inhibition effect on Raji cell proliferation in a concentration-dependent manner. Compared with conventional maytansine and maytansine-NPs, maytansine-NPs-rituximab showed significantly enhanced cytotoxicity and increased cell apoptosis in Raji cells. The maytansine-NPs-rituximab described in this paper might be a potential formulation for targeting chemotherapy and immunotherapy to CD20+ B cell malignancies. 展开更多
关键词 non-hodgkin's lymphoma CD20 monoclonal antibodies apoptosis active targeting nanoparticles chemoimmunotherapy.
下载PDF
Heterochronous multiple primary prostate cancer and lymphoma:A case report
11
作者 Jin-Long Liang Yu-Qing Bu +1 位作者 Li-Li Peng Hong-Zhen Zhang 《World Journal of Clinical Cases》 SCIE 2024年第7期1333-1338,共6页
BACKGROUND Multiple primary malignant tumors(MPMTs)are rare type of cancer,especially when solid tumors are the first and lymphoma is the second primary malignancy.We report a patient with heterochronous MPMTs consist... BACKGROUND Multiple primary malignant tumors(MPMTs)are rare type of cancer,especially when solid tumors are the first and lymphoma is the second primary malignancy.We report a patient with heterochronous MPMTs consisting of prostate cancer and rectal diffuse large B-cell lymphoma(DLBCL).CASE SUMMARY We report a 77-year-old male patient diagnosed with prostate cancer who was treated with radiation therapy and one year of endocrine therapy with bicalutamide(50 mg per day)and an extended-release implant of goserelin(1/28 d).Seven years later,rectal DLBCL with lung metastases was found.CONCLUSION Although rare,the possibility of prostate cancer combined with a double primary cancer of DLBCL can provide a deeper understanding. 展开更多
关键词 Multiple primary malignant tumors Radiation therapy Diffuse large B-cell lymphoma Prostate cancer non-hodgkin lymphoma Case report
下载PDF
Massive bleeding in small intestinal mucosa-associated lymphoid tissue lymphoma associated with COVID-19 infection:a case report
12
作者 Meiling Huang Xiaowei Wu Ji Wang 《Oncology and Translational Medicine》 CAS 2024年第2期93-98,共6页
The increased risk of mucosa-associated lymphoid tissue(MALT)lymphoma is closely associated with chronic antigenic stimulation,with infection being the most common cause of recurrence.Lesions are usually associated wi... The increased risk of mucosa-associated lymphoid tissue(MALT)lymphoma is closely associated with chronic antigenic stimulation,with infection being the most common cause of recurrence.Lesions are usually associated with the gastrointestinal tract,and the involvement of small intestinal is rare.Recent studies have established a close relationship between novel coronavirus 2019(COVID-19)and the occurrence and progression of various diseases.This article presents a rare case of a small intestinal MALT lymphoma.The patient was initially admitted with COVID-19 pneumonia and subsequently developed gastrointestinal bleeding during hospitalization.Medical and endoscopic treatments were ineffective,and an emergency exploratory laparotomy was performed.The affected segment of the small intestine was excised,and a pathological biopsy confirmed the diagnosis of MALT lymphoma.This case underscores the significance of raising clinical awareness of this condition among health care professionals. 展开更多
关键词 COVID-19 non-hodgkin lymphoma small intestine MALT lymphoma Gastrointestinal hemorrhage severe pneumonia
下载PDF
2022 Chinese expert consensus and guidelines on clinical management of toxicity in anti-CD19 chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma 被引量:3
13
作者 Ping Li Yang Liu +37 位作者 Yun Liang Jian Bo Sujun Gao Yongxian Hu Yu Hu He Huang Xiaojun Huang Hongmei Jing Xiaoyan Ke Jianyong Li Yuhua Li Qifa Liu Peihua Lu Heng Mei Ting Niu Yongping Song Yuqin Song Liping Su Sanfang Tu Jianxiang Wang Depei Wu Zhao Wang Kailin Xu Zhitao Ying Qingming Yang Yajing Zhang Fengxia Shi Bin Zhang Huilai Zhang Xi Zhang Mingfeng Zhao Weili Zhao Xiangyu Zhao Liang Huang Jun Zhu Wenbin Qian Weidong Han Aibin Liang 《Cancer Biology & Medicine》 SCIE CAS CSCD 2023年第2期129-146,共18页
Adoptive cellular immunotherapy with chimeric antigen receptor(CAR)T cells has emerged as a novel modality for treating relapsed and/or refractory B-cell non-Hodgkin lymphoma(B-NHL).With increasing approval of CAR T-c... Adoptive cellular immunotherapy with chimeric antigen receptor(CAR)T cells has emerged as a novel modality for treating relapsed and/or refractory B-cell non-Hodgkin lymphoma(B-NHL).With increasing approval of CAR T-cell products and advances in CAR T cell therapy,CAR T cells are expected to be used in a growing number of cases.However,CAR T-cell-associated toxicities can be severe or even fatal,thus compromising the survival benefit from this therapy.Standardizing and studying the clinical management of these toxicities are imperative.In contrast to other hematological malignancies,such as acute lymphoblastic leukemia and multiple myeloma,anti-CD19 CAR T-cell-associated toxicities in B-NHL have several distinctive features,most notably local cytokine-release syndrome(CRS).However,previously published guidelines have provided few specific recommendations for the grading and management of toxicities associated with CAR T-cell treatment for B-NHL.Consequently,we developed this consensus for the prevention,recognition,and management of these toxicities,on the basis of published literature regarding the management of anti-CD19 CAR T-cell-associated toxicities and the clinical experience of multiple Chinese institutions.This consensus refines a grading system and classification of CRS in B-NHL and corresponding measures for CRS management,and delineates comprehensive principles and exploratory recommendations for managing anti-CD19 CAR T-cell-associated toxicities in addition to CRS. 展开更多
关键词 CAR T-cell therapy B-cell non-hodgkin lymphoma TOXICITY cytokine-release syndrome clinical management
下载PDF
Comparison of clinical features of patients with or without severe gastrointestinal complications in aggressive gastrointestinal lymphomas
14
作者 Xiao-Hong Liu Gong Chen +6 位作者 De-Dong Cao Hui Liu Xiao-Kang Ke Yu-Gang Hu Wei Tan Dong Ke Xi-Ming Xu 《World Journal of Gastrointestinal Oncology》 SCIE 2024年第11期4409-4423,共15页
BACKGROUND Aggressive primary gastrointestinal non-Hodgkin lymphoma(PGINHL)is an uncommon and heterogeneous group of lymphoid malignancies,that differs from indolent lymphoma and has a high incidence of severe gastroi... BACKGROUND Aggressive primary gastrointestinal non-Hodgkin lymphoma(PGINHL)is an uncommon and heterogeneous group of lymphoid malignancies,that differs from indolent lymphoma and has a high incidence of severe gastrointestinal complications(GICs).AIM To investigate and compare the clinicopathological characteristics,treatments and outcomes in the GICs and No-GICs group with aggressive PGINHL.METHODS This retrospective analysis was performed on aggressive PGINHL patients between January 2013 and December 2021 at our hospital.The independent influence factors of GICs were obtained by univariate and multivariate Logistic regression analysis,the selected variables significantly related to GICs were selected as the final predictors to construct nomogram.Kaplan-Meier curves further analyzed the survival of patients in GICs and No-GICs groups.Survival analysis of GICs group was performed using Cox regression.RESULTS We focused on 124 aggressive PGINHL cases,which had a relatively high incidence 48.4%(60/124 cases)of GICs,the most common histological type in GICs group was diffuse large B-cell lymphoma(DLBCL)(n=49,81.7%).In the GICs group,small intestine was the most common anatomic site of lesion(43.3%),followed by large intestine(31.7%),and then stomach and esophagus(25.0%).Multivariate Logistic regression analysis showed that the independent risk factors for GICs were the small intestine[odd ratio(OR)=3.33;95%confidence interval(CI):1.47-9.41;P=0.009),aggressive B-cell(OR=0.09;95%CI:0.01-0.83;P=0.033),maximum tumor diameter(OR=1.25;95%CI:1.07-1.47;P=0.005),invaded deep serous layer(OR=3.38;95%CI:1.24-9.19;P=0.017).We developed a nomogram to predict risk of GICs in aggressive PGINHL patients based on independent risk factors.The value of area under curve calculated by receiver operating characteristic curve was 0.815,and calibration curve and decision curve analysis further indicated that the prediction effect was superior.The majority of patients with GICs were given combination therapy(chemotherapy combined with surgery or radiation).Event-free survival and overall survival in GICs group were no worse than those in the No-GICs group.CONCLUSION The complication rate of GICs in patients with aggressive PGINHL was relatively high,particularly in PGI-DLBCL.The independent risk factors for GICs were the small intestine,PGI-TNKL,bulky tumor,and depth of invasion.A combination treatment,involving surgery,improved survival in the GICs group. 展开更多
关键词 Primary gastrointestinal AGGREssIVE non-hodgkin lymphoma Gastrointestinal complication Risk factor
下载PDF
Bruton’s tyrosine kinase inhibitors in primary central nervous system lymphoma:New hopes on the horizon
15
作者 Leonardo S Lino-Silva Sabrina B Martínez-Villavicencio Luisa Fernanda Rivera-Moncada 《World Journal of Clinical Oncology》 2024年第5期587-590,共4页
In this editorial,we comment on the article by Wang et al.This manuscript explores the potential synergistic effects of combining zanubrutinib,a novel oral inhibitor of Bruton’s tyrosine kinase,with high-dose methotr... In this editorial,we comment on the article by Wang et al.This manuscript explores the potential synergistic effects of combining zanubrutinib,a novel oral inhibitor of Bruton’s tyrosine kinase,with high-dose methotrexate(HD-MTX)as a therapeutic intervention for primary central nervous system lymphoma(PCNSL).The study involves a retrospective analysis of 19 PCNSL patients,highlighting clinicopathological characteristics,treatment outcomes,and genomic biomarkers.The results indicate the combination’s good tolerance and strong antitumor activity,with an 84.2%overall response rate.The authors emphasize the potential of zanubrutinib to modulate key genomic features of PCNSL,particularly mutations in myeloid differentiation primary response 88 and cluster of differentiation 79B.Furthermore,the study investigates the role of circulating tumor DNA in cerebrospinal fluid for disease surveillance and treatment response monitoring.In essence,the study provides valuable insights into the potential of combining zanubrutinib with HD-MTX as a frontline therapeutic regimen for PCNSL.The findings underscore the importance of exploring alternative treatment modalities and monitoring genomic and liquid biopsy markers to optimize patient outcomes.While the findings suggest promise,the study’s limitations should be considered,and further research is needed to establish the clinical relevance of this therapeutic approach for PCNSL. 展开更多
关键词 Primary central nervous system lymphoma Zanubrutinib Bruton’s tyrosine kinase PROGNOsIs Myeloid differentiation primary response 88 gene Cluster of differentiation 79B gene
下载PDF
Primary gastric non-Hodgkin lymphomas:Recent advances regarding disease pathogenesis and treatment 被引量:6
16
作者 Michael D Diamantidis Maria Papaioannou Evdoxia Hatjiharissi 《World Journal of Gastroenterology》 SCIE CAS 2021年第35期5932-5945,共14页
Primary gastric lymphomas(PGLs)are distinct lymphoproliferative neoplasms described as heterogeneous entities clinically and molecularly.Their main histological types are diffuse large B-cell lymphoma(DLBCL)or mucosaa... Primary gastric lymphomas(PGLs)are distinct lymphoproliferative neoplasms described as heterogeneous entities clinically and molecularly.Their main histological types are diffuse large B-cell lymphoma(DLBCL)or mucosaassociated lymphoma tissue.PGL has been one of the main fields of clinical research of our group in recent years.Although gastric DLBCLs are frequent,sufficient data to guide optimal care are scarce.Until today,a multidisciplinary approach has been applied,including chemotherapy,surgery,radiotherapy or a combination of these treatments.In this minireview article,we provide an overview of the clinical manifestations,diagnosis and staging of these diseases,along with their molecular pathogenesis and the most important related clinical published series.We then discuss the scientific gaps,perils and pitfalls that exist regarding the aforementioned studies,in parallel with the unmet need for future research and comment on the proper methodology for such retrospective studies.Aiming to fill this gap,we retrospectively evaluated the trends in clinical presentation,management and outcome among 165 patients with DLBCL PGL who were seen in our institutions in 1980-2014.The study cohort was divided into two subgroups,comparing the main 2 therapeutic options[cyclophosphamide doxorubicin vincristine prednisone(CHOP)vs rituximab-CHOP(R-CHOP)].A better outcome with immunochemotherapy(R-CHOP)was observed.In the next 2 mo,we will present the update of our study with the same basic conclusion. 展开更多
关键词 Primary gastric lymphoma Extranodal non-hodgkins lymphoma Diffuse large B-cell lymphoma Mucosa-associated lymphoid tissue IMMUNOCHEMOTHERAPY Rituximab-cyclophosphamide doxorubicin vincristine prednisone
下载PDF
Primary intestinal non-Hodgkin's lymphoma:A clinicopathologic analysis of 81 patients 被引量:16
17
作者 Guo-Bao Wang Guo-Liang Xu +5 位作者 Guang-Yu Luo Hong-Bo Shan Yin Li Xiao-Yan Gao Jian-Jun Li Rong Zhang 《World Journal of Gastroenterology》 SCIE CAS CSCD 2011年第41期4625-4631,共7页
AIM:To analyze the clinicopathologic features and the prognosis of primary intestinal lymphoma.METHODS:Patients were included in the study based on standard diagnostic criteria for primary gastrointesti-nal lymphoma,a... AIM:To analyze the clinicopathologic features and the prognosis of primary intestinal lymphoma.METHODS:Patients were included in the study based on standard diagnostic criteria for primary gastrointesti-nal lymphoma,and were treated at Sun Yat-sen Univer-sity Cancer Centre between 1993 and 2008.RESULTS:The study comprised 81 adults.The most common site was the ileocaecal region.Twenty-two point two percent patients had low-grade B-cell lym-phoma.Fifty-one point nine percent patients had high-grade B-cell lymphoma and 25.9% patients had T-cell lymphoma.Most patients had localized disease.There were more patients and more early stage diseases in the latter period,and the origin sites changed.The ma-jority of patients received the combined treatment,andabout 20% patients only received nonsurgical therapy.The wverall survival and event-free survival rates after 5 years were 71.6% and 60.9% respectively.The mul-tivariate analysis revealed that small intestine and ileo-caecal region localization,B-cell phenotype,and normal lactate dehydrogenase were independent prognostic factors for better patient survival.Surgery based treat-ment did not improve the survival rate.CONCLUSION:Refined stratification of the patients according to the prognostic variables may allow indi-vidualized treatment.Conservative treatment may be an optimal therapeutic modality for selected patients. 展开更多
关键词 Gastrointestinal lymphoma non-hodgkin'slymphoma Gastrointestinal oncology Prognostic factors
下载PDF
A case of primary isolated non-Hodgkin’s lymphoma of the esophagus in an immunocompetent patient 被引量:5
18
作者 Ioannis V Kalogeropoulos Athanasios N Chalazonitis +4 位作者 Sofia Tsolaki Fotios Laspas Nikolaos Ptohis Ioannis Neofytou Dimitra Rontogianni 《World Journal of Gastroenterology》 SCIE CAS CSCD 2009年第15期1901-1903,共3页
Primary non-Hodgkin’s lymphoma of the esophagus is a rare disease.A case of primary isolated nonHodgkin’s lymphoma of the esophagus in a 77-yearold man without acquired immunodeficiency syndrome is presented.We desc... Primary non-Hodgkin’s lymphoma of the esophagus is a rare disease.A case of primary isolated nonHodgkin’s lymphoma of the esophagus in a 77-yearold man without acquired immunodeficiency syndrome is presented.We describe the clinical features and the imaging findings(barium swallow,endoscopic ultrasonography and CT)of a biopsy proven B-cell lymphoma with diffuse transmural involvement of the esophagus wall,which was discovered incidentally.We also briefly review the literature. 展开更多
关键词 Endoscopic ultrasonography EsOPHAGUs lymphoma non-hodgkin's lymphoma
下载PDF
Pediatric-type follicular lymphoma in a Crohn’s disease patient receiving anti-α4β7-integrin therapy:A case report
19
作者 Keval Yerigeri Ilia Buhtoiarov 《World Journal of Gastroenterology》 SCIE CAS 2023年第43期5865-5871,共7页
BACKGROUND Patients with autoimmune conditions receiving immunosuppressants are at risk of non-Hodgkin lymphomas(NHL).Vedolizumab(anti-α4β7-integrin antibody),a treatment-of-choice for Crohn’s disease(CD),reduces i... BACKGROUND Patients with autoimmune conditions receiving immunosuppressants are at risk of non-Hodgkin lymphomas(NHL).Vedolizumab(anti-α4β7-integrin antibody),a treatment-of-choice for Crohn’s disease(CD),reduces inflammatory lymphocyte trafficking into the intestinal mucosa.This effect is believed to be confined to the colon.CASE SUMMARY We report the case of a CD patient on vedolizumab for five years who developed pediatric-type follicular lymphoma.Work-up prior to therapy revealed a reduction in circulating T-lymphocytes and their suppressed response to mitogens.Rituximab,cyclophosphamide,vincristine,and prednisone chemoimmunotherapy resulted in durable lymphoma remission,and vedolizumab treatment was continued.While the patient’s T-lymphocyte population and immunoglobulin production recovered,the T-lymphocyte mitogen response remained suppressed.CONCLUSION This patient’s NHL may be linked to receiving anti-α4β7 therapy.Further research could be beneficial to determine if proactive surveillance for NHL and other systemic diseases is indicated in patients on vedolizumab. 展开更多
关键词 Pediatric-type follicular lymphoma Crohn’s disease Vedolizumab IMMUNOsUPPREssION non-hodgkin lymphoma Case report
下载PDF
HCV infection, B-cell non-Hodgkin's lymphoma and immunochemotherapy: Evidence and open questions 被引量:1
20
作者 Maria Christina Cox Maria Antonietta Aloe-Spiriti +6 位作者 Elena Cavalieri Eleonora Alma Elia Gigante Paola Begini Caterina Rebecchini Gianfranco Delle Fave Massimo Marignani 《World Journal of Gastrointestinal Oncology》 SCIE CAS 2012年第3期46-53,共8页
There is plenty of data confirming that hepatitis C virus (HCV) infection is a predisposing factor for a B-cell non-Hodgkin's lymphoma (B-NHL) outbreak, while relatively few reports have addressed the role of HCV ... There is plenty of data confirming that hepatitis C virus (HCV) infection is a predisposing factor for a B-cell non-Hodgkin's lymphoma (B-NHL) outbreak, while relatively few reports have addressed the role of HCV in affecting B-NHL patients' outcome. HCV infection may influence the short-term outcome of B-NHL because of the emergence of severe hepatic toxicity (HT) during immunochemotherapy. Furthermore, the long term outcome of HCV-related liver disease and patients' quality of life will possibly be affected by Rituximab maintenance, multiple-lines of toxicity during chemotherapy and hematopoietic stem cell transplantation. In this review, data dealing with aggressive and low-grade B-NHL were separately analyzed. The few retrospective papers reporting on aggressive B-NHL patients showed that HCV infection is a risk factor for the outbreak of severe HT during treatment. This adverse event not infrequently leads to the reduction of treatment density and intensity. Existing papers report that low-grade B-NHL patients with HCV infection may have a more widespread disease, more frequent relapses or a lower ORR compared to HCV-negative patients. Notwithstanding, there is no statistical evidence that the prognosis of HCV-positive patients is inferior to that of HCV-negative subjects. HCV-positive prospective studies and longer follow-up are necessary to ascertain if HCV-positive B-NHL patients have inferior outcomes and if there are long term sequels of immunochemotherapies on the progression of liver disease. 展开更多
关键词 Marginal zone lymphoma Diffuse large B cell lymphoma Hepatitis C virus non-hodgkins lymphomas HEPATOTOXICITY Chemotherapy IMMUNOCHEMOTHERAPY Prognosis RITUXIMAB
下载PDF
上一页 1 2 32 下一页 到第
使用帮助 返回顶部